Graduate Institute of Chinese Medicine, School of Chinese Medicine, College of Chinese Medicine, China Medical University, Taichung 404333, Taiwan.
Department of Chinese Medicine, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi 62247, Taiwan.
Medicina (Kaunas). 2023 Mar 30;59(4):683. doi: 10.3390/medicina59040683.
: Sjögren's Syndrome (SS) is a common extra-articular feature among subjects with rheumatoid arthritis (RA). While Chinese herbal medicine (CHM) has been used to treat symptoms of RA for many years, few studies have examined its efficacy in guarding against the SS onset. This study aimed to compare risk of SS for RA patients with and without use of CHM. : Data obtained for this nested case-control study were retrieved from Taiwanese nationwide insurance database from 2000-2013. Cases with SS claims were defined and matched to two randomly selected controls without SS from the recruited RA cohorts. Risk of SS in relation to CHM use was estimated by fitting multiple conditional logistic regression. : Patients aged between 20 and 80 years were included and 916 patients with incident SS were matched to 1832 non-SS controls by age, sex and index year. Among them, 28.1% and 48.4% cases ever received CHM therapy, respectively. After adjusting for baseline characteristics, CHM use was found to be related to a lower risk of SS among them (adjusted odds ratio = 0.40, 95% confidence interval: 0.34-0.47). A dose-dependent, reverse association, was further detected between the cumulative duration of CHM use and SS risk. Those receiving CHM therapy for more than 730 days showed a significantly reduced risk of SS by 83%. : Findings of this study indicated that the add-on CHM formula, as part of RA care, may be a beneficial treatment for prevention against the incident SS.
干燥综合征(SS)是类风湿关节炎(RA)患者常见的关节外表现。虽然中草药(CHM)多年来一直被用于治疗 RA 的症状,但很少有研究探讨其预防 SS 发病的疗效。本研究旨在比较 CHM 使用与不使用的 RA 患者发生 SS 的风险。
这项嵌套病例对照研究的数据来自 2000-2013 年台湾全民保险数据库。通过 SS 索赔定义病例,并从招募的 RA 队列中随机选择两名无 SS 的对照进行匹配。通过拟合多条件逻辑回归估计 CHM 使用与 SS 风险的关系。
纳入年龄在 20-80 岁之间的患者,916 例新发 SS 患者与 1832 例非 SS 对照按年龄、性别和索引年进行匹配。其中,分别有 28.1%和 48.4%的病例曾接受过 CHM 治疗。调整基线特征后,发现 CHM 使用与 SS 风险降低有关(调整后的优势比=0.40,95%置信区间:0.34-0.47)。进一步检测到 CHM 使用累积时间与 SS 风险之间存在剂量依赖性的反向关联。接受 CHM 治疗超过 730 天的患者,SS 风险降低 83%。
本研究结果表明,作为 RA 治疗的一部分,添加的 CHM 配方可能是预防 SS 发病的有益治疗方法。